UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549





FORM
10-K


(Mark
      One):





x
                  ANNUAL
      REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
      OF 1934For
      the fiscal year ended August 31, 2008OR ̈
                  TRANSITION
      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
      OF 1934  For
      the transition period from
                                  
                                  
                                  to





Commission
File Number  0-23559





PERCIPIO
BIOTHERAPEUTICS, INC.


(Exact
Name of Registrant as Specified in its Charter)


Nevada
            
            84-14320001(State
      or other jurisdiction
              of
      incorporation or organization)
            
            (I.R.S.
      Employer
              Identification
      No.)





10990
      Wilshire Blvd., Suite 1410, Los Angeles, CA
            
            90024(Address
      of principal executive offices)
            
            (Zip
      Code)





Registrant's
telephone number, including area code: (866) 963-2220





Securities
registered pursuant to Section 12(b) of the Act: None





Securities
registered pursuant to Section 12(g) of the Act: Common Stock





Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities Act. Yes  ̈    No þ





Indicate
by check mark if the registrant is not required to file reports pursuant to
Section 13 or Section 15(d) of the Act. Yes  ̈    No þ





Indicate
by check mark whether the registrant: (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes þ     No  ̈





Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or
any amendments to this Form 10-K. þ





Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
definitions of "large accelerated filer," "accelerated filer," and "smaller
reporting company" in Rule 12b-2 of the Exchange Act. (Check
one):





Large
      accelerated filer  ̈
            Accelerated
      filer  ̈Non-accelerated
      filer  ̈  (Do
      not check if a smaller reporting company)
            Smaller
      reporting company þ





Indicate
by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes  ̈    No þ





State the
aggregate market value of the voting and non-voting common equity held by
non-affiliates computed by reference to the price at which the common equity was
last sold, or the average bid and asked price of such common equity, as of the
last business day of the registrant’s most recently completed second fiscal
quarter. The registrant’s common stock was not trading publicly as of February
29, 2008, the last business day of the registrant’s most recently completed
second fiscal quarter.





Indicate
the number of shares outstanding of each of the registrant’s classes of common
stock, as of the latest practicable date.  As of February 9, 2009,
there were 14,891,031 shares of the registrant’s common stock
outstanding.





Table of
Contents




PART
      IItem 1.
                    Business
                    2Item
      1A.
                    Risk Factors
                    4Item
      1B.
                    Unresolved
      Staff Comments
                    4Item
      2.
                    Properties
                    4Item
      3.
                    Legal
      Proceedings
                    4Item
      4.
                    Submission
      of Matters to a Vote of Security Holders
                    4PART
      IIItem
      5.
                    Market
      for Common Equity, Related Stockholder Matters and Issuer Purchases of
      Equity Securities
                    5Item 6.
                    Selected
      Financial Data
                    5Item
      7.
                    Management’s
      Discussion and Analysis of Financial Condition and Results of
      Operations
                    6Item 7A.
                    Quantitative
      and Qualitative Disclosures About Market Risk
                    8Item
      8
                    Financial
      Statements and Supplementary Data
                    9Item
      9.
                    Changes
      in and Disagreements With Accountants on Accounting and Financial
      Disclosure
                    10Item
      9A(T)
                    Controls
      and Procedures
                    10Item 9B.
                    Other
      Information
                    11PART IIIItem 10.
                    Directors,
      Executive Officers and Corporate Governance
                    12Item
      11.
                    Executive
      Compensation
                    13Item
      12.
                    Security
      Ownership of Certain Beneficial Owners and Management and Related
      Stockholder Matters
                    14Item
      13.
                    Certain
      Relationships and Related Transactions, and Director
      Independence
                    15Item 14.
                    Principal
      Accounting Fees and Services
                    16PART
      IVItem
      15.
                    Exhibits,
      Financial Statement Schedules
                    17




i


PART
I





Item
1. Business





Company
Overview





Percipio
Biotherapeutics, Inc. (f/k/a Sunburst Acquisitions III, Inc.) ((“Percipio” or
the “Company”) was incorporated
under the laws of the State of Colorado on August 27, 1997, andis a
development-stage biotechnology company based in Los Angeles.  In
August 2008, the Company issued convertible notes in the amount of $150,000 and
entered into a license agreement which gives the company exclusive rights to
protein therapeutics being developed for the treatment of cancer and
drug-resistant bacterial infections (e.g. MRSA).





On
September 30, 2008, the Company consummated a migratory merger whereby Sunburst
Acquisition III, Inc., a Colorado corporation was merged into Sunburst
Acquisition III, Inc., a Nevada corporation.  The Nevada entity was a
newly formed wholly-owned subsidiary of the Company.





Effective
October 29, 2008, the Company changed its name to Percipio Biotherapeutics, Inc.
The name change was effectuated by merging a wholly owned subsidiary of the
Company into the Company with the Company as the surviving entity.




In
addition, effective October 29, 2008, the Company effected a reverse split of
its issued and outstanding shares of common stock as well as it authorized
shares of common stock on a 67 for one basis.  In accordance with
Nevada law, the Company obtained approval of the Board of Directors to implement
the reverse split.  As a result of the reverse split, the authorized
shares of common stock will be reduced from 1,000,000,000 to
14,925,373.  Further, the issued and outstanding shares prior to the
reverse stock split of 997,699,062 will be 14,891,031 following the reverse
stock split.  Including the shares outstanding and options to be
issued to management, the fully-diluted shares outstanding following the reverse
stock split will be 18,275,081 shares.




PRIOR
BUSINESS ACTIVITIES




As of
August 30, 1999, the Company entered into an Agreement and Plan of
Reorganization with American Recruitment Conferences, Inc., a California
corporation ("ARC"), and Workseek.com, a California corporation ("Workseek").
ARC and Workseek, which are affiliated companies, were to be acquired by the
Company in a reverse acquisition transaction, resulting in the shareholders of
ARC and Workseek obtaining control over the Company. A series of transactions
were contemplated by the agreement with ARC, including implementation of a
16.16-to-1 forward split, voluntary surrender for cancellation of shares by the
existing shareholders of the Company, and issuance of new shares to the ARC and
Workseek shareholders.





In
contemplation of the ARC/Workseek acquisition, the contemplated forward split
was completed and shares of the Company's Common Stock were sold in a private
placement in August and September 1999, with the cash proceeds loaned to ARC. In
the private placement, a total of 1,000,000 post-split shares were sold for
$1,400,000 in cash and $600,000 in receivables assigned to the Company. Also in
contemplation of completion of the ARC/Workseek acquisition, a total of
8,015,360 common shares were voluntarily surrendered for cancellation by Company
officers and other shareholders.





The
ARC/Workseek acquisition was not completed, and no payments were made under the
terms of the promissory note. Collection of the promissory note is considered
doubtful.


Efforts
by Company management to negotiate some type of final resolution of the matter
were not successful. As a result, the note has been offset by a full allowance
for realization and no further efforts to resolve the matter either through
negotiation or legal action are expected or contemplated.





CURRENT
BUSINESS ACTIVITIES





The
Company is currently engaged in preclinical development of PB102 and PB108,
including the preparation and revision of clinical development plans
..  In addition, the Company is seeking additional financing to further
develop its internal drug candidates (PB102 and PB108) and to launch an internal
drug discovery program, which will seek combination therapies for drug-resistant
bacterial infections and diseases of aging.  There is no guarantee
that we will be successful in obtaining financing at all or if we do obtain
financing that such financing will be on acceptable terms.  Our
efforts are supported in part through academic collaborations with researchers
from the United States and the United Kingdom.


2





PB102 is
a chimeric monoclonal anti-CD55 antibody, which was originally licensed from and
developed by Cancer Research Technology and Dr. Lindy Durrant at the University
of Nottingham.  CD55 protein is expressed at high density on the
surface of most cancer cells and acts as a ‘mask’ to hide cancer cells from
immune system.  Because of this, the anti-CD55 monoclonal antibody has
multiple potential therapeutic uses.  These include use as a
monotherapy, in combination with existing therapeutics (e.g. Rituxan), or as a
vehicle for cancer-specific toxin delivery.





Colorectal
cancer monotherapy is a likely indication for PB102. Targeted cancer therapies
do not typically replace other drugs.  They are often added to therapy
regimes, having the effect of adding to the total colorectal cancer
market.  Some regimes are also increasing from two to three drugs,
creating additional market opportunity.  In addition to colorectal
cancer, CD55 has broad applicability in other cancers given that CD55 is
over-expressed on 80% of solid tumors as well as in some
lymphomas.  This includes potential for treating breast and lung
cancers as well.  The parent antibody of PB102 has already been used
safely in over 100 human patients in diagnostic cancer imaging
studies.  This data, along with in silico studies performed
on the chimeric version indicate promise that PB102 will be safe and
non-immunogenic.





PB108 is
a novel cytokine that is attractive as a novel anti-bacterial agent for
antibiotic-resistant infections.  In vivo studies in mice have
demonstrated that PB108 was able to induce a memory humoral immune response to
MRSA. These results suggest that PB108 may have utility as an antibacterial
agent when used on a preventative basis, or post-infection. The type of immune
response generated also demonstrates its potential utility as a vaccine
adjuvant. Furthermore and importantly, unlike conventional antibiotics, PB108 is
not directly susceptible to the development of pathogen resistance and so may
have particular utility in the hospital setting.





Methicillin-resistant
Staphylococcus aureus
(MRSA) is responsible for various infections which may lead to death at
times.  We believe there is continued strong demand for therapeutics
that have favorable safety profiles and are unlikely to be susceptible to
bacterial resistance.





Internal
drug discovery work will focus on the screening of libraries of approved drugs
for cocktail therapies in two primary areas: (1) MRSA and other
antibiotic-resistant bacterial infections; and (2) diseases of aging as
evidenced in model organism lifespan studies and other physiological and
biochemical biomarkers.  Through partnership with a collaborator,
stochastic search algorithms will be employed to discover efficacious
combination therapies.





License
Agreements





On August
21, 2008, the Company entered into two exclusive intellectual property licensing
agreements (the "Licenses") with Hamilton Atlantic (the "Licensee"), a Cayman
Islands company.  One of the Licenses is for certain intellectual property
that may be useful in development of a therapeutic for human cancers (the
"Cancer Therapeutic License").  The other License is for intellectual
property that may be useful in development of therapeutics for
antibiotic-resistant bacterial infections, including MRSA (the "MRSA Therapeutic
License").  The Cancer Therapeutic License provides the Company with the
exclusive right to utilize the intellectual property to develop products
worldwide.  The MRSA Therapeutic License provides the Company with the
exclusive right to utilize the intellectual property to develop products
worldwide, except the Company did not license the right to develop therapeutics
for MRSA and C.difficile, which both are
types of antibiotic-resistant bacterial infections, within the countries of the
European Union. Under the terms of the Licenses, the Company is required to pay
the Licensee 1% of net sales on all licensed products and 2% of all payments
received by the Company through sub-licensee fees for any products developed
using the intellectual property.  All payments are due within 30
business days of the end of each quarter and 6% interest shall accrue on all
payments the Company fails to make.  The intellectual property subject
to the Licenses is in the development stage and there is no guarantee that the
Company will be able to commercially exploit such intellectual
property.


3





On
October 21, 2008, the Company entered into an exclusive and worldwide license
agreement (the “License”) with Cancer Research Technology
(“CRT”).  The License, in combination with license agreements entered
into by the Company on August 21, 2008 with Hamilton Atlantic, provides the
Company with exclusive and worldwide rights necessary for the development of
products derived from monoclonal antibodies previously discovered by researchers
funded by Cancer Research UK.  For the License, the Company will make
upfront payments to CRT and for any therapeutic products developed using the
intellectual property, the Company will owe royalties to CRT based on gross
sales revenue or any sub-license fees received.  Upon any of the
products obtaining significant regulatory or marketing designations, the Company
will be responsible for making milestone payments to CRT.  For
therapeutic products, no milestone payments will be due until a product receives
an Investigational New Drug designation.  The License describes a
development plan that must be followed by the Company.  The
intellectual property subject to the License is in the development stage and
there is no guarantee that the Company will be able to commercially exploit such
intellectual property.





Item
1A.  Risk Factors.





Not
required.





Item
1B.  Unresolved Staff Comments.





Not
required.





Item
2.  Properties.




We
currently operate from the offices of Bristol Capital Advisors, LLC at 10990
Wilshire Blvd., Suite 1410, Los Angeles, California. Bristol Capital Advisers,
LLC is the investment manager of Bristol Investment Fund, Ltd., which holds a
significant equity stake in the Company.  In addition, our Chief
Financial Officer is also a director of Bristol Investment Fund, Ltd. (see
section entitled “Certain Relationships and Related Transactions”).





Item
3.  Legal Proceedings.





From time
to time, we may become involved in various lawsuits and legal proceedings, which
arise in the ordinary course of business. However, litigation is subject to
inherent uncertainties, and an adverse result in these or other matters may
arise from time to time that may harm our business. We are currently not aware
of any such legal proceedings or claims that we believe will have, individually
or in the aggregate, a material adverse affect on our business, financial
condition or operating results.





Item 4.  Submission of Matters to a Vote of
Security Holders.





No
matters were submitted to a vote of security holders during the fourth quarter
of the fiscal year ended August 31, 2008.


4


PART
II





Item 5.  Market for Common Equity, Related
Stockholder Matters and Issuer Purchases of Equity
Securities.




Market
Information




At this
time there is no public trading market for our common stock. As of February 9,
2009, we have a total of 14,891,031 shares of our common stock
outstanding.




Holders




We
currently have 79 record holders of our common stock.




Dividends




We have
not paid any cash dividends and we currently intend to retain any future
earnings to fund the development and growth of our business. Any future
determination to pay dividends on our common stock will depend upon our results
of operations, financial condition and capital requirements, applicable
restrictions under any credit facilities or other contractual arrangements and
such other factors deemed relevant by our Board of Directors.




Equity
Compensation Plan Information




Information
relating to compensation plans under which our equity securities are authorized
for issuance is set forth in Item 12 of this report under “Security Ownership of
Certain Beneficial Owners and Management and Related Stockholder
Matters.”





Item
6. Selected Financial Data





Not
required


5


Item
7.  Management's Discussion and Analysis of Financial Condition and
Results of Operations




The
following discussion and analysis of our results of operations and financial
condition for the years ended August 31, 2008 and 2007 should be read in
conjunction with our financial statements and the notes to those financial
statements that are included elsewhere in this report. Our discussion includes
forward-looking statements based upon current expectations that involve risks
and uncertainties, such as our plans, objectives, expectations and intentions.
Actual results and the timing of events could differ materially from those
anticipated in these forward-looking statements as a result of a number of
factors, including those set forth under the “Business” section and elsewhere in
this report. We use words such as “anticipate,” “estimate,” “plan,” “project,”
“continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,”
“could,” and similar expressions to identify forward-looking statements. All
forward-looking statements included in this report are based on information
available to us on the date hereof and, except as required by law, we assume no
obligation to update any such forward-looking statements.




Overview




Percipio
Biotherapeutics, Inc.( f/k/a Sunburst Acquisitions III,
Inc.)  (“Percipio” or the “Company”) was incorporated under the laws
of the State of Colorado on August 27, 1997, and is a development-stage
biotechnology company based in Los Angeles.  In August 2008, the
Company issued convertible notes in the amount of $150,000 and entered into a
license agreement which gives the company exclusive rights to protein
therapeutics being developed for the treatment of cancer and drug-resistant
bacterial infections (e.g. MRSA).




Prior to
August 2008 the Company's only activities had consisted of the raising of
capital and efforts to seek one or more properties or businesses for
acquisition.




From the
date of filing of its registration statement under the Securities Exchange Act
of 1934 (December 29, 1997) until the end of the fourth quarter of its 2001
fiscal year, the Company filed all required periodic reports under the
Securities Exchange Act of 1934. After completing the filing of the report on
Form 10KSB for the fiscal year ended August 31, 2001, the Company ceased filing
reports in order to avoid incurring additional legal and accounting
expenses.  The Company recently resumed reporting under the Exchange
Act.




After the
2001 fiscal year, the Company remained dormant throughout the fiscal years
ending August 31, 2002 and August 31, 2003. The Company incurred total of $3,344
and $3,413 in legal and professional fees in 2005 and 2006, related primarily to
catch-up filings with the Securities and Exchange Commission.




The
Company's plan of operations since August 31, 2001 was to remain dormant in
order to avoid incurring legal and accounting fees related to compliance with
its reporting obligations. However, in February 2004 there was a change of
control, and the Company elected to begin taking the steps necessary to file all
delinquent reports and to once again become current in compliance with its
reporting obligations under the Securities Exchange Act of 1934.




In July
2008 the holders of all of the outstanding notes payable converted their notes
into shares of the Company’s common stock  as provided for under the
terms of the notes at a price of $0.0015 per common share.




On July
28, 2008, the Company issued notes convertible into the Company’s common shares
to three (3) investors.  As a consequence of the difficulty in
obtaining financing, in lieu of interest and as additional financing costs, the
Company issued 906,912,000  shares of the Company’s common stock to
the holders of the notes, giving the investors, as a group, control over the
Company.  We valued the shares issued to these investors at $0.0015
per share based on the conversion price at which the prior noteholders had
recently converted their notes.  We recorded a total of $1,360,368 in
financing costs on this transaction.




On August
6, 2008. the Company hired a new Chief Executive Officer, Robert Brooke, and
Chief Financial Officer, Richard McKilligan.





On August
21, 2008, the Company entered into a license agreement with Hamilton Atlantic,
which gives the Company exclusive
rights to protein therapeutics being developed for the treatment of cancer and
drug-resistant bacterial infections (e.g. MRSA).  Hamilton Atlantic is
owned by two of the three holders of the notes that the Company issued on July
28, 2008.


6


Plan of Operations in the
next 12 months





Our plan
of operation for the remainder of the current fiscal year and for the next
fiscal year is to attempt to secure financing in order to develop the protein
therapeutics under the license agreement with Hamilton Atlantic.




The
Company will require additional capital in order to meet its cash needs for the
next year, including the costs of compliance with the continuing reporting
requirements of the Securities Exchange Act of 1934, as amended.




During
the period from inception to July 28, 2008, the Company had engaged in no
significant operations other than organizational activities, acquisition of
capital, preparation and filing of the registration of its securities under the
Securities Exchange Act of 1934, as amended, compliance with its periodical
reporting requirements, and efforts to locate a suitable merger or acquisition
candidate including the Workseek transaction disclosed above. No revenues were
received by the Company during this period.




Liquidity
and Capital Resources




As of
August 31, 2008, the Company remains in the development stage. For the fiscal
years ended August 31, 2008 and 2007, the Company's balance sheet reflects
current asset and total assets of $139,141 and $155, respectively, and total
current liabilities of $17,509 and $67,105, respectively.




On July
28, 2008, the Company issued notes convertible into the Company’s common shares
to three (3) investors.  As a consequence of the difficulty in
obtaining financing, in lieu of interest and as additional financing costs, the
Company issued 13,536,000 shares (906,912,000 shares before the effect of the
reverse split) of the Company’s common stock to the holders of the notes, giving
the investors, as a group, control over the Company.  We valued the
shares issued to these investors at $0.0015 per share based on the conversion
price at which the prior noteholders had recently converted their
notes.  We recorded a total of $1,360,368 in financing costs on this
transaction.




The
Company is currentlyseeking
additional financing to develop internal drug discovery efforts seeking
combination therapies for drug-resistant bacterial infections and diseases of
aging.  The Company expects that it will need $250,000 for the next 12
months.  There is no guarantee that we will be successful in obtaining
financing at all or if we do obtain financing that such financing will be on
terms acceptable.




Results
of Operations




During
the period from August 27, 1997 (inception) through August 31, 2007, the Company
had accumulated a deficit of $2,140,153.  This deficit is primarily
the result of a $2,000,000 valuation allowance taken against a promissory note
from American Recruitment Conferences, Inc., a California corporation ("ARC")
and Workseek.com, Inc., a California corporation ("Workseek"). The Workseek
promissory note was issued to the Company to evidence a loan made in conjunction
with execution of an Agreement and Plan of Reorganizaton with ARC and Workseek,
dated August 30, 1999. The proposed transaction was not consummated and recovery
of the amount due under the promissory note was doubtful. As a result, as of
August 31, 2000, the promissory note receivable was offset by a full allowance
for realization.




During
the year ended August 31, 2008, the Company incurred a net loss of $1,746,789,
primarily attributable to the  financing costs amounting to
$1,360,368, associated with the July 2008 note issuance which were paid in the
form of the Company’s commons shares and the fair value of the vested stock
options granted to employees amounting to $338,329.




7




Off
Balance Sheet Arrangements




The
Company does not have any Off-Balance Sheet arrangements.





Item
7A.  Quantitative and Qualitative Disclosures About Market
Risk.





Not
required.


8


Item
8.  Financial Statements and Supplementary Data.




INDEX
TO FINANCIAL STATEMENTS
  PageReport
      of Independent Registered Public Accounting Firms
                  
                  
                  F-1Balance
      Sheets at August 31, 2008 and 2007
                  
                  
                  F-3Statements
      of Operations for the Years Ended August 31, 2008 and 2007,
                    and
      August 27, 1997 (Inception) to August 31, 2008
(Cumulative)
                  
                  
                  F-4Statements
      of Stockholders’ Equity (Deficiency) from August 27, 1997
      (Inception)
                    to
      August 31, 2008
                  
                  
                  F-5Statements
      of Cash Flows for the Years Ended August 31, 2008 and 2007,
                    and
      August 27, 1997 (Inception) to August 31, 2008
(Cumulative)
                  
                  
                  F-6Notes
      to Financial Statements for the Years Ended August 31, 2008 and
      2007
                  
                  
                  F-7




9




REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM





To the
Board of Directors


Percipio
Biotherapeutics, Inc.


(Formerly
Sunburst Acquisitions, III)


Los
Angeles, California





We have
audited the balance sheet of Percipio Biotherapeutics, Inc. (formerly Sunburst
Acquisitons, III), a development stage company, (the “Company”) as of August 31,
2008, and the related statements of operations, stockholders’ deficiency and
cash flows for the year then ended. These financial statements are the
responsibility of the Company’s management. Our responsibility is to express an
opinion on these financial statements based on our audit.





We
conducted our audit in accordance with standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audits to obtain reasonable assurance whether the consolidated
financial statements are free of material misstatement. The Company is not
required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audit included consideration of internal
control over financial reporting as a basis for designing audit procedures that
are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company’s internal control over financial
reporting. Accordingly, we express no such opinion. An audit includes examining,
on a test basis, evidence supporting the amounts and disclosures in the
financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.





In our
opinion, the financial statements referred to above present fairly, in all
material respects, the financial position of Percipio Biotherapeutics, Inc. as
of August 31, 2008 and the results of its operations and its cash flows for the
year then ended in conformity with accounting principles generally accepted in
the United States of America.





The
accompanying financial statements have been prepared assuming that the Company
will continue as a going concern. As discussed in Note 1 to the financial
statements, the Company has not yet commenced any revenue generating operations
which has resulted in a stockholders' deficiency. These factors raise
substantial doubt about the Company's ability to continue as a going concern.
Management's plans in regard to these matters are also described in Note 1. The
financial statements do not include any adjustments that might result from the
outcome of this uncertainty.





Weinberg
and Company, P.A.





January
16, 2009


Los
Angeles, California





F-1




Larry
O'Donnell, CPA, P.C.
 Telephone
      (303) 745-4545
                  2228
      South Fraser StreetUnit
      1Aurora,
      Colorado 80014
 
 Report
of Independent Registered Public Accounting Firm
 
 
 Board of
Directors
 Percipio
Biotherapeutics, Inc. formerly Sunburst Acquisition III, Inc.
 
 I have
audited the accompanying balance sheet of Percipio Biotherapeutics, Inc.Sunburst Acquisition III, Inc. as of August 31, 2007, and the related
statements of operations, changes in stockholders’ equity and cash flows for
each of the two fiscal years then ended and for the period from inception August
27, 1997 to August 31, 2007.  These financial statements are the
responsibility of the Company’s management.  My responsibility is to
express an opinion on these financial statements based on my
audits.
 
 I
conducted my audit in accordance with standards of the Public Company Accounting
Oversight Board (United States).   Those standards require that I
plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement.  An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements.  An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement
presentation.  I believe that my audits provide a reasonable basis for
my opinion.
 
 In my
opinion, the financial statements referred to above present fairly, in all
material respects, the financial position of Percipio Biotherapeutics, Inc.
Sunburst Acquisition III, Inc. as of August 31, 2007, and the results of its
operations and their cash flows for each of the two fiscal years then ended and
for the period from inception August 27, 1997 to August 31, 2007, in conformity
with generally accepted accounting principles in the United States of
America.
 
 
 Larry
O'Donnell, CPA, P.C.
 
 October
17, 2007
  F-2




Percipio
Biotherapeutics, Inc.


(Formerly
Sunburst Acquisitions III, Inc.)


(A
development stage company)


Balance
Sheets





August 31,
                              
                              
                              August 31,2008
                              
                              
                              2007ASSETSCURRENT
      ASSETSCash
      and cash equivalents
                              
                              $
                              133,725
                              
                              
                              $
                              155Other
      current assets
                              
                              
                              2,500
                              
                              
                              
                              -TOTAL
      CURRENT ASSETS
                              
                              
                              136,225
                              
                              
                              
                              155PROPERTY
      AND EQUIPMENT, net of accumulated
      depreciation of $0 and $0
                              
                              
                              2,916
                              
                              
                              
                              -TOTAL
      ASSETS
                              
                              $
                              139,141
                              
                              
                              $
                              155LIABILITIES
      AND STOCKHOLDERS' DEFICIENCYCURRENT
      LIABILITIESAccounts
      payable
                              
                              $
                              8,759
                              
                              
                              $
                              -Due
      to employees
                              
                              
                              8,750
                              
                              
                              
                              -10%
      Convertible notes payable
                              
                              
                              -
                              
                              
                              
                              67,105TOTAL
      CURRENT LIABILITIES
                              
                              
                              17,509
                              
                              
                              
                              67,105Convertible
      notes payable
                              
                              
                              150,000
                              
                              
                              
                              -TOTAL
      LIABILITIES
                              
                              
                              167,509
                              
                              
                              
                              67,105COMMITMENTS
      AND CONTINGENCIESSTOCKHOLDERS'
      DEFICIENCYPreferred
      stock; $0.0001 par value; 100,000,000 shares authorized; no shares issued
      and outstandingCommon
      stock; $0.0001 par value; 1,000,000,000 shares authorized; 14,891,031 and
      497,072 shares issued and outstanding
                              
                              
                              1,490
                              
                              
                              
                              50Additional
      paid-in capital
                              
                              
                              3,857,084
                              
                              
                              
                              2,073,153Accumulated
      deficit
                              
                              
                              (3,886,942
                              )
                              
                              
                              (2,140,153
                              )TOTAL
      STOCKHOLDERS' DEFICIENCY
                              
                              
                              (28,368
                              )
                              
                              
                              (66,950
                              )TOTAL
      LIABILITIES AND STOCKHOLDERS' DEFICIENCY
                              
                              $
                              139,141
                              
                              
                              $
                              155





See notes
to financial statements





F-3




Percipio
Biotherapeutics, Inc.


(Formerly
Sunburst Acquisitions III, Inc.)


(A
development stage company)


Statements
of Operations





For the years ended August 31,
                    
                    
                    For theperiod
                      fromAugust
                      27,1997
                      (Inception) to
                      August 31,2008
                    
                    
                    2007
                    
                    
                    2008REVENUES
                    
                    $
                    -
                    
                    
                    $
                    -
                    
                    
                    $
                    1,066GENERAL
      AND ADMINISTRATIVE EXPENSES:Salaries
      and wages
                    
                    
                    347,079
                    
                    
                    
                    -
                    
                    
                    
                    347,079Other
      expenses
                    
                    
                    33,822
                    
                    
                    
                    15,987
                    
                    
                    
                    2,164,141LOSS
      FROM OPERATIONS
                    
                    
                    (380,901
                    )
                    
                    
                    (15,987
                    )
                    
                    
                    (2,510,154
                    )OTHER
      EXPENSESFinancing
      cost
                    
                    
                    1,360,368
                    
                    
                    
                    
                    
                    
                    
                    1,360,368Interest
      expense
                    
                    
                    5,520
                    
                    
                    
                    4,605
                    
                    
                    
                    16,420NET
      LOSS
                    
                    $
                    (1,746,789
                    )
                    
                    $
                    (20,592
                    )
                    
                    $
                    (3,886,942
                    )NET
      LOSS PER SHARE:BASIC
      AND DILUTED
                    
                    $
                    (1.03
                    )
                    
                    $
                    (0.04
                    )WEIGHTED
      AVERAGE SHARES OUTSTANDING:BASIC
      AND DILUTED
                    
                    
                    1,696,569
                    
                    
                    
                    497,072





See notes
to financial statements





F-4




Percipio
Biotherapeutics, Inc.


(Formerly
Sunburst Acquisitions III, Inc.)


(A
development stage company)


Statement
of Stockholders' Deficiency





Common
                  
                  
                  Additional
                  
                  
                  
                  
                  
                  TotalPreferred Stock
                  
                  
                  Common stock
                  
                  
                  Stock
                  
                  
                  paid-in
                  
                  
                  Accumulated
                  
                  
                  stockholders'Shares
                  
                  
                  Amount
                  
                  
                  Shares
                  
                  
                  Amount
                  
                  
                  Subscribed
                  
                  
                  capital
                  
                  
                  Deficit
                  
                  
                  equityPreferred
      stock issued for cash, August 27,1997 at $0.001 per share
                  
                  
                  1,194
                  
                  
                  $
                  8,000
                  
                  
                  
                  -
                  
                  
                  $
                  -
                  
                  
                  $
                  -
                  
                  
                  $
                  -
                  
                  
                  $
                  -
                  
                  
                  $
                  8,000Common
      stock issued for services, August 27, 1997 at $0.000062 per
      share
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  466,711
                  
                  
                  
                  47
                  
                  
                  
                  -
                  
                  
                  
                  1,888
                  
                  
                  
                  -
                  
                  
                  
                  1,935Net
      loss for the period ended August 31, 1997
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (1,935
                  )
                  
                  
                  (1,935
                  )Balance,
      August 31, 1997
                  
                  
                  1,194
                  
                  
                  
                  8,000
                  
                  
                  
                  466,711
                  
                  
                  
                  47
                  
                  
                  
                  -
                  
                  
                  
                  1,888
                  
                  
                  
                  (1,935
                  )
                  
                  
                  8,000Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  600
                  
                  
                  
                  
                  
                  
                  
                  600Common
      stock issued for services, August 1998 at $0.00186 per
    share
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  24,120
                  
                  
                  
                  2
                  
                  
                  
                  -
                  
                  
                  
                  2,998
                  
                  
                  
                  -
                  
                  
                  
                  3,000Net
      loss for the period ended August 31, 1998
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (10,305
                  )
                  
                  
                  (10,305
                  )Balance,
      August 31, 1998
                  
                  
                  1,194
                  
                  
                  
                  8,000
                  
                  
                  
                  490,831
                  
                  
                  
                  49
                  
                  
                  
                  -
                  
                  
                  
                  5,486
                  
                  
                  
                  (12,240
                  )
                  
                  
                  1,295Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  600
                  
                  
                  
                  
                  
                  
                  
                  600Common
      stock issued for services, January 1999 at $0.00155 per
    share
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  72,359
                  
                  
                  
                  7
                  
                  
                  
                  -
                  
                  
                  
                  7,493
                  
                  
                  
                  -
                  
                  
                  
                  7,500Preferred
      stock converted to common, May 1999 at $0.00309 per share
                  
                  
                  (1,194
                  )
                  
                  
                  (8,000
                  )
                  
                  
                  38,592
                  
                  
                  
                  4
                  
                  
                  
                  -
                  
                  
                  
                  7,996
                  
                  
                  
                  -
                  
                  
                  
                  0Common
      stock subscribed, year ended August 31, 1999
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  2,000,000
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  2,000,000Net
      loss for the period ended August 31, 1999
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (9,031
                  )
                  
                  
                  (9,031
                  )Balance,
      August 31, 1999
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  601,782
                  
                  
                  
                  60
                  
                  
                  
                  2,000,000
                  
                  
                  
                  21,575
                  
                  
                  
                  (21,271
                  )
                  
                  
                  2,000,364Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  600
                  
                  
                  
                  
                  
                  
                  
                  600Issuance
      of commons stock subscribed, September 1999 at $2.00 per
    share
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  14,926
                  
                  
                  
                  2
                  
                  
                  
                  (2,000,000
                  )
                  
                  
                  1,999,998
                  
                  
                  
                  -
                  
                  
                  
                  0Voluntary
      cancellation of outstanding shares, September 1999
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  (119,636
                  )
                  
                  
                  (12
                  )
                  
                  
                  
                  
                  
                  
                  12
                  
                  
                  
                  -
                  
                  
                  
                  0Expenses
      paid by shareholder
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  1,444
                  
                  
                  
                  -
                  
                  
                  
                  1,444Net
      loss for the period ended August 31, 2000
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (2,022,917
                  )
                  
                  
                  (2,022,917
                  )Balance,
      August 31, 2000
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  497,072
                  
                  
                  
                  50
                  
                  
                  
                  -
                  
                  
                  
                  2,023,629
                  
                  
                  
                  (2,044,188
                  )
                  
                  
                  (20,509
                  )Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  600
                  
                  
                  
                  
                  
                  
                  
                  600Expenses
      paid by shareholder
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  30,962
                  
                  
                  
                  -
                  
                  
                  
                  30,962Net
      loss for the period ended August 31, 2001
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (14,361
                  )
                  
                  
                  (14,361
                  )Balance,
      August 31, 2001
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  497,072
                  
                  
                  
                  50
                  
                  
                  
                  -
                  
                  
                  
                  2,055,191
                  
                  
                  
                  (2,058,549
                  )
                  
                  
                  (3,308
                  )Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  600
                  
                  
                  
                  
                  
                  
                  
                  600Expenses
      paid by shareholder
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  11,884
                  
                  
                  
                  -
                  
                  
                  
                  11,884Net
      loss for the period ended August 31, 2002
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (9,168
                  )
                  
                  
                  (9,168
                  )Balance,
      August 31, 2002
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  497,072
                  
                  
                  
                  50
                  
                  
                  
                  -
                  
                  
                  
                  2,067,675
                  
                  
                  
                  (2,067,717
                  )
                  
                  
                  8Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  600
                  
                  
                  
                  
                  
                  
                  
                  600Net
      loss for the period ended August 31, 2003
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (2,478
                  )
                  
                  
                  (2,478
                  )Balance,
      August 31, 2003
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  497,072
                  
                  
                  
                  50
                  
                  
                  
                  -
                  
                  
                  
                  2,068,275
                  
                  
                  
                  (2,070,195
                  )
                  
                  
                  (1,870
                  )Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  600
                  
                  
                  
                  
                  
                  
                  
                  600Expenses
      paid by shareholder
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  1,540
                  
                  
                  
                  -
                  
                  
                  
                  1,540Net
      loss for the period ended August 31, 2004
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (22,348
                  )
                  
                  
                  (22,348
                  )Balance,
      August 31, 2004
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  497,072
                  
                  
                  
                  50
                  
                  
                  
                  -
                  
                  
                  
                  2,070,415
                  
                  
                  
                  (2,092,543
                  )
                  
                  
                  (22,078
                  )Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  600
                  
                  
                  
                  
                  
                  
                  
                  600Expenses
      paid by shareholder
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  100
                  
                  
                  
                  -
                  
                  
                  
                  100Net
      loss for the period ended August 31, 2005
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (8,094
                  )
                  
                  
                  (8,094
                  )Balance,
      August 31, 2005
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  497,072
                  
                  
                  
                  50
                  
                  
                  
                  -
                  
                  
                  
                  2,071,115
                  
                  
                  
                  (2,100,637
                  )
                  
                  
                  (29,472
                  )Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  600
                  
                  
                  
                  
                  
                  
                  
                  600Expenses
      paid by shareholder
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  838
                  
                  
                  
                  -
                  
                  
                  
                  838Net
      loss for the period ended August 31, 2006
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (18,924
                  )
                  
                  
                  (18,924
                  )Balance,
      August 31, 2006
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  497,072
                  
                  
                  
                  50
                  
                  
                  
                  -
                  
                  
                  
                  2,072,553
                  
                  
                  
                  (2,119,561
                  )
                  
                  
                  (46,958
                  )Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  600
                  
                  
                  
                  
                  
                  
                  
                  600Net
      loss for the period ended August 31, 2007
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (20,592
                  )
                  
                  
                  (20,592
                  )Balance,
      August 31, 2007
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  497,072
                  
                  
                  
                  50
                  
                  
                  
                  -
                  
                  
                  
                  2,073,153
                  
                  
                  
                  (2,140,153
                  )
                  
                  
                  (66,950
                  )Rent
      at no charge
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  -
                  
                  
                  
                  449
                  
                  
                  
                  
                  
                  
                  
                  449Notes
      converted into common at $0.0015 per share
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  857,959
                  
                  
                  
                  86
                  
                  
                  
                  
                  
                  
                  
                  86,139
                  
                  
                  
                  -
                  
                  
                  
                  86,225Fair
      value of shares issued as financing costs at $0.0015 per
    share
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  13,536,000
                  
                  
                  
                  1,354
                  
                  
                  
                  
                  
                  
                  
                  1,359,014
                  
                  
                  
                  -
                  
                  
                  
                  1,360,368Fair
      value of options issued to employees
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  338,329
                  
                  
                  
                  
                  
                  
                  
                  338,329Net
      loss for the period ended August 31, 2008
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  (1,746,789
                  )
                  
                  
                  (1,746,789
                  )Balance,
      August 31, 2008
                  
                  
                  -
                  
                  
                  $
                  -
                  
                  
                  
                  14,891,031
                  
                  
                  $
                  1,490
                  
                  
                  $
                  -
                  
                  
                  $
                  3,857,084
                  
                  
                  $
                  (3,886,942
                  )
                  
                  $
                  (28,368
                  )





See notes
to financial statements





F-5




Percipio
Biotherapeutics, Inc.


(Formerly
Sunburst Acquisitions III, Inc.)


(A
development stage company)


Statements
of Cash Flows





For
      the periodfromYears
                                
                                
                                August 27, 1997ended August 31,
                                
                                
                                (Inception) to2008
                                
                                
                                2007
                                
                                
                                August 31, 2008CASH
      FLOWS FROM OPERATING ACTIVITIES:Net
      loss
                                
                                $
                                (1,746,789
                                )
                                
                                $
                                (20,592
                                )
                                
                                $
                                (3,886,942
                                )Adjustment to
      reconcile net loss to net cash used
      in operating activities:Fair
      value of vested stock options
                                
                                
                                338,329
                                
                                
                                
                                -
                                
                                
                                
                                338,329Fair
      value of shares issued as financing cost
                                
                                
                                1,360,368
                                
                                
                                
                                
                                
                                
                                
                                1,360,368Rent
      and other expenses recorded as contributed capital
                                
                                
                                449
                                
                                
                                
                                600
                                
                                
                                
                                53,216Fair
      value of common stock issued as consulting fees
                                
                                
                                
                                
                                
                                
                                
                                
                                
                                
                                4,935Changes
      in assets and liabilities:Other
      current assets
                                
                                
                                (2,500
                                )
                                
                                
                                -
                                
                                
                                
                                (2,500
                                )Accounts
      payable and accrued liabilities
                                
                                
                                8,759
                                
                                
                                
                                -
                                
                                
                                
                                8,759Due
      to employees
                                
                                
                                8,750
                                
                                
                                
                                -
                                
                                
                                
                                8,750Accrued
      interest on notes payable
                                
                                
                                5,520
                                
                                
                                
                                -
                                
                                
                                
                                16,420Net
      cash used in operating activities
                                
                                
                                (27,114
                                )
                                
                                
                                (19,992
                                )
                                
                                
                                (2,098,665
                                )CASH
      FLOWS FROM INVESTING ACTIVITIES:Purchase
      of furniture and equipment
                                
                                
                                (2,916
                                )
                                
                                
                                -
                                
                                
                                
                                (2,916
                                )Net
      cash used in investing activities
                                
                                
                                (2,916
                                )
                                
                                
                                -
                                
                                
                                
                                (2,916
                                )CASH
      FLOWS FROM FINANCING ACTIVITIES:Issuance
      of convertible notes payable
                                
                                
                                163,600
                                
                                
                                
                                18,605
                                
                                
                                
                                219,805Issuance
      of common stock
                                
                                
                                
                                
                                
                                
                                
                                
                                
                                
                                2,015,501Net
      cash provided by financing activities
                                
                                
                                163,600
                                
                                
                                
                                18,605
                                
                                
                                
                                2,235,306NET
      INCREASE (DECREASE) IN CASH ANDCASH
    EQUIVALENTS
                                
                                
                                133,570
                                
                                
                                
                                (1,387
                                )
                                
                                
                                133,725CASH
      AND CASH EQUIVALENTS, Beginning of period
                                
                                
                                155
                                
                                
                                
                                1,542
                                
                                
                                
                                -CASH
      AND CASH EQUIVALENTS, End of period
                                
                                $
                                133,725
                                
                                
                                $
                                155
                                
                                
                                $
                                133,725SUPPLEMENTAL
      DISCLOSURES OF CASH FLOW INFORMATION:Taxes
      paid
                                
                                $
                                -
                                
                                
                                $
                                -
                                
                                
                                $
                                -Interest
      paid
                                
                                $
                                -
                                
                                
                                $
                                -
                                
                                
                                $
                                -SUPPLEMENTAL
      DISCLOSURES OF NON-CASH INVESTING AND FINANCING
ACTIVITIES:Conversion
      of notes payable and interest to common stock
                                
                                $
                                86,225
                                
                                
                                
                                -
                                
                                
                                $
                                86,225





See notes
to financial statements




F-6




PERCIPIO
BIOTHERAPEUTICS, INC.




(FORMERLY
SUNBURST ACQUISITIONS III, INC.)




(A
development stage company)




NOTES
TO THE FINANCIALS STATEMENTS FOR THE YEARS




ENDED
AUGUST 31, 2008 AND 2007




1.        Organization




Sunburst
Acquisitions III, Inc. was incorporated under the laws of the State of Colorado
on August 27, 1997, and is a development stage company. On August 22, 2008, the
Company’s board of directors approved the Migratory Merger which is pursuant to
an agreement and plan of merger between Sunburst Acquisitions III, inc. a
Colorado company and Sunburst Acquisitions III, Inc., a Nevada corporation (“New
Company”).





The
Migratory Merger will effect a change in the legal domicile of the Company from
Colorado to Nevada.  In addition, upon consummation of the Migratory
Merger, the daily business operations of New Company will continue as they are
presently conducted by the Company, at the Company's principal executive offices
at 10990 Wilshire Blvd., Suite 1410, Los Angeles, California 90024. The
authorized capital stock of New Company will consist of 1,000,000,000 shares of
New Company Common Stock and 100,000,000 shares of preferred stock, $0.0001 par
value per share.





Effective
October 29, 2008, the Company changed its name from Sunburst Acquisitions III,
Inc. to Percipio Biotherapeutics, Inc. The name change was effectuated by
merging a wholly owned subsidiary of the Company into the Company with the
Company as the surviving entity.




Also
effective October 29, 2008, the Company effected a reverse split of its issued
and outstanding shares of common stock as well as it authorized shares of common
stock on a sixty-seven (67) for one basis.  In accordance with Nevada
law, the Company obtained approval of the Board of Directors to implement the
reverse split.  As a result of the reverse split, the authorized
shares of common stock was reduced from 1,000,000,000 to
14,925,373.  Further, the issued and outstanding shares prior to the
reverse stock split of 997,699,062 are 14,891,081 following the reverse stock
split.  Including the shares outstanding and options to be issued to
management, the fully-diluted shares outstanding following the reverse stock
split was 18,275,081 shares.  The outstanding shares and per share
calculations have been retroactively adjusted to effect the reverse split as if
it occurred at the beginning of the earliest period presented.





The
Company is considered a “development stage company” as defined in SFAS No. 7,
“Accounting and Reporting by Development Stage Enterprises”, as it has not yet
commenced any revenue-generating operations, does not have any cash flows from
operations, and is dependent on debt and equity financing to finance its
operations.  The Company has selected August 31 as its fiscal year
end.




F-7





The
Company’s financial statements have been prepared assuming that the Company will
continue as a going concern, which contemplates the realization of the Company’s
assets and the satisfaction of its liabilities. The Company is in the
development stage and has not generated revenues from operations to
date.





The
Company is currently seeking additional financing to develop internal drug
discovery efforts seeking combination therapies from drug-resistant bacterial
infections and diseases of aging.





Since
inception, the Company has not yet commenced any revenue generating
operations.  Through August 31, 2008, the Company has incurred
accumulated losses of approximately $3,886,000. Successful completion of the
Company’s development programs and its transition to attaining profitable
operations is dependent upon obtaining financing adequate to complete its
product development and the successful market


introduction
of its product and services.




2.        Summary of Significant
Accounting Policies




Loss
per Share





We
compute net loss per share in accordance with SFAS No. 128, Earnings Per Share(“SFAS
128”). Under the provisions of SFAS 128, basic loss per share is computed by
dividing net loss by the weighted average number of common stock shares
outstanding during the periods presented. Diluted earnings would customarily
include, if dilutive, potential common stock shares issuable upon the exercise
of stock options and warrants. The dilutive effect of outstanding stock options
and warrants is reflected in earnings per share in accordance with SFAS 128 by
application of the treasury stock method. For the periods presented, the
computation of diluted loss per share equaled basic loss per share as the
inclusion of any dilutive instruments would have had an antidilutive effect on
the earnings per share calculation in the periods presented.





The
following potential common shares have been excluded from the computation of
diluted net loss per share since their effect would have been
antidilutive:





For the Year EndedAugust 31,2008
                  
                  
                  2007Stock
      Options
                  
                  
                  3,384,000
                  
                  
                  
                  -




Financial
Instruments




The
carrying amounts reported in the balance sheets for cash and cash equivalents,
other current assets, accounts payable and due to employees approximate fair
value because of the immediate or short-term maturity of these items. The
carrying amounts of convertible notes payable approximate fair value, because
the related effective rates on these instruments approximate rates currently
available to the Company.




F-8




Cash
and Cash Equivalents




For
purposes of the statements of cash flows, the Company considers all highly
liquid debt instruments purchased with an original maturity of three months or
less to be cash equivalents.




Use
of Estimates




The
preparation of the Company's financial statements in conformity with generally
accepted accounting principles requires the Company's management to make
estimates and assumptions that affect the amounts reported in these financial
statements and accompanying notes. Actual results could differ from those
estimates.





Impairment
of Long-Lived Assets





SFAS No.
144, “Accounting for the Impairment or Disposal of Long-Lived Assets” requires
that long-lived assets to be disposed of by sale, including those of
discontinued operations, be measured at the lower of carrying amount or fair
value less cost to sell, whether reported in continuing operations or in
discontinued operations. SFAS No. 144 also establishes a “primary-asset”
approach to determine the cash flow estimation period for a group of assets and
liabilities that represents the unit of accounting for a long-lived asset to be
held and used. Management regularly reviews property, equipment and other
long-lived assets for possible impairment in accordance with SFAS No. 144 and
based upon this review believes there is no impairment at August 31, 2008 or
2007.




Stock
Based Compensation




The
Company periodically issues stock options and warrants to employees and
non-employees in capital raising transactions, for services and for financing
costs. The Company adopted SFAS No. 123R effective January 1, 2006, and is using
the modified prospective method in which compensation cost is recognized
beginning with the effective date (a) based on the requirements of SFAS No. 123R
for all share-based payments granted after the effective date and (b) based on
the requirements of SFAS No. 123R for all awards granted to employees prior to
the effective date of SFAS No. 123R that remain unvested on the effective
date.




The
Company accounts for stock option and warrant grants issued and vesting to
non-employees in accordance with EITF No. 96-18: “Accounting for Equity
Instruments that are Issued to Other Than Employees for Acquiring, or in
Conjunction with Selling, Goods or Services” and EITF No. 00-18: “Accounting
Recognition for Certain Transactions involving Equity Instruments Granted to
Other Than Employees” whereas the value of the stock compensation is based upon
the measurement date as determined at either a) the date at which a performance
commitment is reached, or b) at the date at which the necessary performance to
earn the equity instruments is complete.




F-9




Income
Taxes





Income
taxes are accounted for under SFAS No. 109, Accounting for Income Taxes(“SFAS 109”), using the liability method. Under SFAS 109, deferred tax
assets and liabilities are determined based on differences between financial
reporting and tax basis of assets and liabilities, and are measured using the
enacted tax rates and laws that are expected to be in effect when the
differences reverse. Valuation allowances are established when necessary to
reduce deferred tax assets to the amounts expected to be realized.





The
significant components of the provision for income taxes for the years ended
August 31, 2008 and 2007 were $0 and $0, respectively, for the current
state provision. There was no state deferred or federal tax
provision.





Due to
our current net loss position, we have provided a valuation allowance in full on
our net deferred tax assets in accordance with SFAS 109 and in light of the
uncertainty regarding ultimate realization of the net deferred tax
assets.




Recently
Issued Accounting Pronouncements




In
September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements," which
provides enhanced guidance for using fair value to measure assets and
liabilities. SFAS No. 157 provides a common definition of fair value and
establishes a framework to make the measurement of fair value in generally
accepted accounting principles more consistent and comparable. SFAS No. 157 also
requires expanded disclosures to provide information about the extent to which
fair value is used to measure assets and liabilities, the methods and
assumptions used to measure fair value, and the effect of fair value measures on
earnings. SFAS No. 157 is effective for financial statements issued in fiscal
years beginning after November 15, 2007 and to interim periods within those
fiscal years.





In
February 2007, the Financial Accounting Standards Board (FASB) issued SFAS
Statement No. 159, “The Fair Value Option for Financial Assets and Financial
Liabilities – Including an amendment of FASB Statement No. 115” (SFAS
159).  SFAS 159, which becomes effective for the Company on January 1,
2008, permits companies to choose to measure many financial instruments and
certain other items at fair value and report unrealized gains and losses in
earnings.  Such accounting is optional and is generally to be applied
instrument by instrument.




F-10




In
December 2007, the FASB issued FASB Statement No. 141 (R), “Business
Combinations” (“FAS 141(R)”), which establishes accounting principles and
disclosure requirements for all transactions in which a company obtains control
over another business. FAS 141 (R) applies prospectively to business
combinations for which the acquisition date is on or after the beginning of the
first annual reporting period beginning
on or after December 15, 2008. Earlier adoption is prohibited.





In
December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in
Consolidated Financial Statements, an amendment of ARB No. 51”. SFAS No. 160
establishes accounting and reporting standards that require that the ownership
interests in subsidiaries held by parties other than the parent be clearly
identified, labeled, and presented in the consolidated statement of financial
position within equity, but separate from the parent’s equity; the amount of
consolidated net income attributable to the parent and to the noncontrolling
interest be clearly identified and presented on the face of the consolidated
statement of income; and changes in a parent’s ownership interest while the
parent retains its controlling financial interest in its subsidiary be accounted
for consistently. SFAS No. 160 also requires that any retained noncontrolling
equity investment in the former subsidiary be initially measured at fair value
when a subsidiary is deconsolidated. SFAS No. 160 also sets forth the disclosure
requirements to identify and distinguish between the interests of the parent and
the interests of the noncontrolling owners. SFAS No. 160 applies to all entities
that prepare consolidated financial statements, except not-for-profit
organizations, but will affect only those entities that have an
outstanding noncontrolling interest in one or more subsidiaries or that
deconsolidate a subsidiary. SFAS No. 160 is effective for fiscal years, and
interim periods within those fiscal years, beginning on or after December 15,
2008. Earlier adoption is prohibited. SFAS No. 160 must be applied prospectively
as of the beginning of the fiscal year in which it is initially applied, except
for the presentation and disclosure requirements. The presentation and
disclosure requirements are applied retrospectively for all periods
presented.





In March
2008, the FASB issued SFAS No. 161 (FAS 161), “Disclosures About Derivative
Instruments and Hedging Activities an amendment of FAS 133.” FAS 161 requires
qualitative disclosures about objectives and strategies for using derivatives,
quantitative disclosures about fair value amounts of gains and losses on
derivative instruments, and disclosures about credit-risk-related contingent
features in derivative agreements.
FAS 161 is effective for fiscal years beginning after November 15, 2008. The
Company does not expect the implementation of FAS 161 to have a material impact
on its consolidated financial statements.





The
Company does not believe that the adoption of the above recent pronouncements
will have a material effect on the Company’s consolidated results of operations,
financial position, or cash flows.





F-11




3.           Property and
Equipment





Property
and equipment consists of the following as of August 31, 2008 and
2007:





August 31,
                              2008
                            
                            August 31,
                              2007Computer
      equipment
                            
                            $
                            2,916
                            
                            
                            $
                            -2,916
                            
                            
                            
                            -Less
      accumulated depreciation
                            
                            
                            (0
                            )
                            
                            
                            -$
                            2,916
                            
                            
                            $
                            -




The
computer equipment was acquired at the end of the fiscal year and no
depreciation expense was recorded for the years ended August 31, 2008 or
2007.




4.        Convertible Notes
Payable




Convertible
notes payable consist of the following as of August 31, 2008 and
2007:




August 31,
                                                    2008
                                                  
                                                  
                                                  August 31,
                                                    2007(a)
      Convertible notes payable
                                                  
                                                  $
                                                  150,000
                                                  
                                                  
                                                  $
                                                  -(b)
      10% Convertible notes payable
                                                  
                                                  –
                                                  
                                                  
                                                  
                                                  67,105150,000
                                                  
                                                  
                                                  
                                                  67,105Less
      current portion
                                                  
                                                  
                                                  -
                                                  
                                                  
                                                  
                                                  67,105Long
      term
                                                  
                                                  $
                                                  150,000
                                                  
                                                  
                                                  $
                                                  -




(a)           On
July 28, 2008, the Company entered into a financing agreement with three (3)
accredited investors pursuant to which the Company issued convertible promissory
notes in the principal amount of $150,000.  The notes are non-interest
bearing, unsecured with maturity date of August 6, 2010.  As a
consequence of the difficulty in obtaining financing, in lieu of interest and as
additional financing costs, the Company issued 13,536,000 shares of the
Company’s common stock to the holders of the notes, giving the investors, as a
group, control over the Company.  We valued the shares issued to these
investors at $0.0015 per share based on the conversion price at which the prior
noteholders had recently converted their notes.  We recorded a total
of $1,360,368 in financing costs on this transaction that is reflected in the
accompanying statement of operations for the year ended August 31,
2008.




F-12





The
Convertible notes mature on the second anniversary of the date of issuance (the
"Maturity Date").  The Company may prepay the notes at anytime upon
five days written notice to the holder.  If upon the closing of
the  Company’s next equity financing in which the Company sells
newly-issued shares of its equity securities or securities convertible into
equity securities and the Company receives gross cash proceeds of $1,000,000 or
more  (the “Subsequent Financing”) on or before the Maturity Date, the
investors may elect to (i) convert the outstanding principal of the notes into
the securities issued in connection with such Subsequent Financing at a
conversion price equal to 75% of the per share or unit purchase price of the
Subsequent Financing  or (ii) receive payment in cash of the
outstanding amount due under the notes.




(b)           Prior
to August 31, 2007, the Company issued $67,105 of 10% convertible notes to
various shareholders.  The Company issued an additional $13,600 of
these notes during the year ended August 31, 2008.  The notes plus
interest were due within thirty days after a demand is made in writing by the
holders.  The notes were secured by all assets of the
Company.  In July 2008 the holders of all of the 10% notes payable,
amounting to $86,225, including $16,420 of accrued interest, converted their
notes into 857,959 shares of the Company’s common stock as provided for under
the terms of the notes at a price of $0.0015 per common share.




5.        Stock
Options





On August
6, 2008 the Company granted options to purchase 3,384,000 shares (after giving
effect to the reverse split) of common stock to its management with an exercise
price of $0.00067 per share.   The options vested immediately and
were valued at $338,329 using a Black-Scholes valuation model with the following
assumptions; no dividend yield, risk free interest rate of 4.5%, expected
volatility of 150%, and an expected term of the options of three years. Stock
based compensation expense of $338,329 and $0 were recognized during the years
ended August 31, 2008 and 2007.




At August
31, 2008 options outstanding are as follows:





Number of
                    Options
                  
                  
                  Weighted
                    Average
                    Exercise
                    PriceBalance
      at September 1, 2007
                  
                  
                  —
                  
                  
                  $
                  0.00Granted
                  
                  
                  3,384,000
                  
                  
                  $
                  0.00067Exercised
                  
                  
                  —
                  
                  
                  
                  —Cancelled
                  
                  
                  —
                  
                  
                  $
                  0.00Balance
      at August 31, 2008
                  
                  
                  3,384,000
                  
                  
                  $
                  0.00067




F-13




As of
August 31, 2008, all of the outstanding stock options were exercisable and had
no intrinsic value.




6.        Related Party
Transactions




Until
August 1, 208, the Company's former President provided office space at no charge
to the Company. For purposes of the financial statements, the Company accrued
$450 during the year ended August 31, 2008 as additional paid-in capital for
this use.





On August
21, 2008, the Company entered into a license agreement with Hamilton Atlantic,
which gives the Company exclusive rights to protein therapeutics being developed
for the treatment of cancer and drug-resistant bacterial infections (e.g.
MRSA).  Hamilton Atlantic is owned by two of the three holders of the
notes and common stock that the Company issued on July 28, 2008 in a transaction
that gave control of the Company to those three stockholders as a
group.




7. Income
Taxes




The
Company has Federal net operating loss carryforwards of approximately $2,137,000
expiring during the years 2018 and 2027. The tax benefit of these net operating
losses is approximately $427,000 and has been offset by a full allowance for
realization. This carryforward may be limited upon the consummation of a
business combination under IRC Section 381.  For the years ended August 31,
2008 and 2007, the valuation allowance increased by approximately $4,000 and
$3,600, respectively.




8. Subsequent
Events




On
December 12, 2008, the Company amended its Certificate of Incorporation to
increase the number of authorized shares of common stock from 14,925,373 shares
to 250,000,000 shares and authorized shares of preferred stock, par value $.0001
per share from 1,492,537 shares to 10,000,000 shares.





Also on
December 12, 2008, the Company adopted the 2008 Equity Compensation Plan, which
reserves 6,000,000 shares of common stock to be awarded under the
plan.  The Company granted 3,384,000 options expiring on August
6, 2013 at an exercise price of $0.00067 per share to management on December 12,
2008.




F-14


Item
9.  Changes in and Disagreements With Accountants on Accounting and
Financial Disclosure.




There
were no changes in or disagreements with our accountants on accounting and
financial disclosure during the last two fiscal years.




Item9A
(T).  Controls and Procedures




Management’s
Report on Disclosure Controls and Procedures




We
maintain disclosure controls and procedures that are designed to ensure that
information required to be disclosed in our reports filed under the Securities Exchange Act of
1934, as amended, is recorded, processed, summarized and reported within
the time periods specified in the Securities and Exchange Commission's rules and
forms, and that such information is accumulated and communicated to our
management, including our president and chief executive officer (who is acting
as our principal executive officer) and our principal financial officer and
principle accounting officer to allow for timely decisions regarding required
disclosure.




As of
August 31, 2008, the end of our fiscal year covered by this report, we carried
out an evaluation, under the supervision and with the participation of our Chief
Executive Officer and Chief Financial Officer, of the effectiveness of the
design and operation of our disclosure controls and procedures. Based on the
foregoing, our Chief Executive Officer and Chief Financial Officer concluded
that our disclosure controls and procedures were effective as of the end of the
period covered by this annual report.




Management’s
Report on Internal Control over Financial Reporting




Our
management is responsible for establishing and maintaining adequate internal
control over financial reporting. Responsibility, estimates and judgments by
management are required to assess the expected benefits and related costs of
control procedures. The objectives of internal control include providing
management with reasonable, but not absolute, assurance that assets are
safeguarded against loss from unauthorized use or disposition, and that
transactions are executed in accordance with management’s authorization and
recorded properly to permit the preparation of consolidated financial statements
in conformity with accounting principles generally accepted in the United
States. Our management assessed the effectiveness of our internal control over
financial reporting as of August 31, 2008. In making this assessment, our
management used the criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated
Framework. Our management has concluded that, as of August 31, 2008, our
internal control over financial reporting is effective in providing reasonable
assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with US generally
accepted accounting principles. Our management reviewed the results of their
assessment with our Board of Directors.




This
annual report does not include an attestation report of our company’s registered
public accounting firm regarding internal control over financial reporting.
Management’s report was not subject to attestation by our company’s registered
public accounting firm pursuant to temporary rules of the Securities and
Exchange Commission that permit our company to provide only management’s report
in this annual report.




Inherent
limitations on effectiveness of controls




Internal
control over financial reporting has inherent limitations which include but is
not limited to the use of independent professionals for advice and guidance,
interpretation of existing and/or changing rules and principles, segregation of
management duties, scale of organization, and personnel factors. Internal
control over financial reporting is a process which involves human diligence and
compliance and is subject to lapses in judgment and breakdowns resulting from
human failures. Internal control over financial reporting also can be
circumvented by collusion or improper management override. Because of its
inherent limitations, internal control over financial reporting may not prevent
or detect misstatements on a timely basis, however these inherent limitations
are known features of the financial reporting process and it is possible to
design into the process safeguards to reduce, though not eliminate, this risk.
Therefore, even those systems determined to be effective can provide only
reasonable assurance with respect to financial statement preparation and
presentation. Projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures
may deteriorate.




10


Changes
in Internal Control over Financial Reporting





There
have been no changes in our internal controls over financial reporting that
occurred during the year ended August 31, 2008 that have materially or are
reasonably likely to materially affect, our internal controls over financial
reporting.





Item
9B.  Other Information.





None




11


PART
III





Item
10.  Directors, Executive Officers and Corporate
Governance




The
following table identifies our current executive officers and directors, their
respective offices and positions, and their respective dates of election or
appointment:







Name
              
              Age
              
              Position
              
              Date of AppointmentRobert
      Brooke
              
              28
              
              Chief
      Executive Officer
              
              August
      6, 2008Richard
      McKilligan
              
              45
              
              Chief
      Financial Officer, Secretary and General Counsel
              
              August
      6, 2008




All
directors hold office until the next annual meeting of stockholders and the
election and qualification of their successors. Officers are elected annually by
the Board of Directors and serve at the discretion of the Board.




Business
Experience Descriptions




Robert
Brooke – President and Chairman





Robert
Brooke joined Percipio as its Chief Executive Officer in August
2008.  Since July 2004, he was an analyst with Bristol Capital
Advisors, LLC, investment manager to Bristol Investment Fund, Ltd.(“Bristol”)
which holds a significant equity stake in the Company.  He currently
is a Member of the Los Angeles Gerontology Research Group.  He earned
a B.S. in Electrical Engineering from Georgia Tech in 2003 and a M.S. in
Biomedical Engineering from UCLA in 2005.




Richard
McKilligan – Chief Financial Officer




Richard
McKilligan earned his law degree from Cornell Law School, his MBA from the
University of Chicago and his undergraduate degree in Accountancy from the
University of Illinois at Urbana-Champaign. He joined Percipio in August 2008.
Mr. McKilligan is also  a director of Bristol Investment Fund, Ltd.,
which holds a significant equity stake in the Company, and Chief Financial
Officer of Derycz Scientific, Inc. of which Bristol Investment Fund, Ltd. also
holds a significant equity stake. He was an associate with Morgan, Lewis &
Bockius, LLP in their New York and London offices from 2000 until January 2006.
He is a member of the State Bar of California, the New York State Bar
Association and the Florida Bar.




Family
Relationships




There are
no family relationships among any of our executive officers or
directors.




Involvement
in Certain Legal Proceedings


None of
the directors or executive officers have, during the past five
years:





(a)
            had
      any petition under the federal bankruptcy laws or any state insolvency law
      filed by or against, or a receiver, fiscal agent or similar officer
      appointed by a court for the business or property of, such person, or any
      partnership in which he was a general partner at or within two years
      before the time of such filing, or any corporation or business association
      of which he was an executive officer at or within two years before the
      time of such filing;(b)
            been
      convicted in a criminal proceeding or subject to a pending criminal
      proceeding (excluding traffic violations and other minor
      offenses);(c)
            been
      subject to any order, judgment, or decree, not subsequently reversed,
      suspended or vacated, of any court of competent jurisdiction or any
      federal or state authority, permanently or temporarily enjoining, barring,
      suspending or otherwise limiting his involvement in any type of business,
      securities, futures, commodities or banking activities;
  or(d)
            been
      found by a court of competent jurisdiction (in a civil action), the SEC or
      the Commodity Futures Trading Commission to have violated a federal or
      state securities or commodities law, and the judgment or finding has not
      been reversed, suspended, or
vacated.”




12




Code
of Ethics
  We have
not yet adopted a written code of ethics that applies to our Chief Executive
Officer, Chief Financial Officer, principal accounting officer or persons
performing similar functions. We currently are considering the terms of such a
code and expect to adopt a code of ethics during the current fiscal
year.
 
 Item
11.  Executive Compensation.
  Executive
Compensation
  The
following table summarizes all compensation for the last two fiscal years
awarded to, earned by or paid to our “named executive officers,” which group
includes the Company’s Chief Executive Officer and the Company’s two most highly
compensated executive officers who earned more than $100,000 in the last two
fiscal years.
  SUMMARY
COMPENSATION TABLE
 
 Name and principle
                                                position
                                              
                                              Year
                                              
                                              Salary
                                                ($)
                                              
                                              
                                              Bonus
                                                ($)
                                              
                                              
                                              Stock
                                                awards
                                                ($)
                                              
                                              
                                              Option
                                                awards
                                                ($)
                                              
                                              
                                              Non-equity
                                                incentive
                                                plan
                                                compensation
                                                ($)
                                              
                                              
                                              Nonqualified
                                                deferred
                                                compensation
                                                earnings
                                                ($)
                                              
                                              
                                              All other
                                                compensation
                                                ($)
                                              
                                              
                                              Total
                                                ($)(a)
                                              
                                              (b)
                                              
                                              (c)
                                              
                                              
                                              (d)
                                              
                                              
                                              (e)
                                              
                                              
                                              (f)
                                              
                                              
                                              (g)
                                              
                                              
                                              (h)
                                              
                                              
                                              (i)
                                              
                                              
                                              (j)Robert
      Brooke
                                              
                                              2008
                                              
                                              
                                              -
                                              (1)
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              253,747
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              253,747Chief
      Executive Officer
                                              
                                              2007
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -Richard
      McKilligan
                                              
                                              2008
                                              
                                              
                                              -
                                              (1)
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              84,582
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              84,582Chief
      Financial Officer
                                              
                                              2007
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
                                              
                                              
                                              
                                              -
 
 (1)
                No
      compensation was paid to either Mr. Brooke or Mr. McKilligan until
      September 2008. However, the Company accrued salary payable
      of  $6,250 for Mr. Brooke and $2,500 for Mr. McKilligan in
      August 2008
 
 The
following table sets forth, at August 31, 2008, information regarding
unexercised options for each named executive officer.  There were no
stock awards outstanding at June 30, 2008.
 
 OUTSTANDING
EQUITY AWARDS AT FISCAL YEAR-END
 
 Name
                                          
                                          Number of
                                            securities
                                            underlying
                                            unexercised
                                            options
                                            (#)
                                            exercisable
                                          
                                          
                                          Number of
                                            securities
                                            underlying
                                            unexercised
                                            options
                                            (#)
                                            unexercisable
                                          
                                          
                                          Equity incentive
                                            plan awards:
                                            Number of
                                            securities
                                            underlying
                                            unexercised
                                            unearned options
                                            (#)
                                          
                                          
                                          Option
                                            exercise price
                                            ($)
                                          
                                          Option
                                            expiration
                                            date(a)
                                          
                                          (b)
                                          
                                          
                                          (c)
                                          
                                          
                                          (d)
                                          
                                          
                                          (e)
                                          
                                          (f)Robert
      Brooke
                                          
                                          
                                          -
                                          
                                          
                                          
                                          2,538,000
                                          (1)
                                          
                                          
                                          -
                                          
                                          
                                          $
                                          .00067
                                          
                                          8/6/13Richard
      McKilligan
                                          
                                          
                                          -
                                          
                                          
                                          
                                          846,000
                                          (1)
                                          
                                          
                                          -
                                          
                                          
                                          $
                                          .00067
                                          
                                          8/6/13
 
 (1)
                  Options
      vested immediately upon grant on August 6, 2008, however, the authorized
      shares of the Company were insufficient at the time of grant to issue the
      options so the options were issued in December 2008, after adoption of the
      2008 Equity Compensation
Plan.
  13
  The
following table sets forth, for the year ended August 31, 2008, the compensation
earned by our directors for the services rendered by them to the Company in all
capacities.
 
 DIRECTOR
COMPENSATION
 
 Name
                  
                  Fees
                    earned
                    or paid
                    in cash
                    ($)
                  
                  
                  Stock
                    awards
                    ($)
                  
                  
                  Option
                    awards
                    ($)
                  
                  
                  Non-equity
                    incentive plan
                    compensation
                    ($)
                  
                  
                  Nonqualified
                    deferred
                    compensation
                    earnings
                    ($)
                  
                  
                  All other
                    compensation
                    ($)
                  
                  
                  Total
                    ($)(a)
                  
                  (b)
                  
                  
                  (c)
                  
                  
                  (d)
                  
                  
                  (e)
                  
                  
                  (f)
                  
                  
                  (g)
                  
                  
                  (h)Robert
      Brooke
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -Richard
      McKilligan
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
                  
                  
                  
                  -
 
 Employment
Agreements
  Robert
Brooke
  Mr.
Brooke’s  employment contract as Chief Executive Officer and as a
director of the Company has a two year term beginning August 6, 2008. The
contract provides an annual salary of $75,000 and included a grant of options to
purchase 170,046,000 common shares (2,538,000 shares after giving effect to the
reverse stock split) of the Company at an exercise price of $.00001 per share to
be issued as soon as practicable after sufficient common shares have been
authorized under the Company’s Articles of Incorporation.  No part of
Mr. Brooke’s salary is allocated to his duties as a director of the Company. The
contract contains no other incentive bonus structure.
  Richard
McKilligan
  Mr.
McKilligan’s  employment contract as Chief Financial Officer and as a
director of the Company has a two year term beginning August 6 2008. The
contract provides an annual salary of $30,000 and included a grant of options to
purchase 56,682,000 common shares (846,000 shares after giving effect to the
reverse stock split) of the Company at an exercise price of $.00001 per share to
be issued as soon as practicable after sufficient common shares have been
authorized under the Company’s Articles of Incorporation.  No part of
Mr. McKilligan’s salary is allocated to his duties as a director of the Company.
The contract contains no other incentive bonus structure
  Director Compensation
  We intend
to compensate non-management directors through stock option and/or restricted
stock granted under our 2008 Equity Compensation Plan. At this time, no
directors receive compensation for their services as directors.
 
 Item 12.  Security Ownership of
Certain Beneficial Owners and Management and Related Stockholder
Matters.
  The
following table sets forth certain information, as of February 9, 2009, with
respect to the holdings of (1) each person who is the beneficial owner of more
than five percent of our common stock, (2) each of our directors, (3) the CEO
and each named executive officer, and (4) all of our directors and executive
officers as a group.
  Beneficial
ownership of the common stock is determined in accordance with the rules of the
Securities and Exchange Commission and includes any shares of common stock over
which a person exercises sole or shared voting or investment powers, or of which
a person has a right to acquire ownership at any time within 60 days of February
9, 2009. Except as otherwise indicated, and subject to applicable community
property laws, the persons named in this table have sole voting and investment
power with respect to all shares of common stock held by them. Applicable
percentage ownership in the following table is based on 14,891,031 shares of
common stock outstanding as of February 9, 2009, plus, for each person, any
securities that person has the right to acquire within 60 days of February 9,
2009.
  Unless
otherwise indicated below, the address of each of the principal shareholders is
c/o Percipio Biotherapeutics, Inc., 10990 Wilshire Blvd., Suite 1410, Los
Angeles, California 90024.
 
 14
  Name and Address
                  
                  Shares
                    Beneficially
                    Owned
                  
                  
                  Percentage
                    of ClassBristol
      Investment Fund, Ltd. (1)
                  
                  
                  6,429,600
                  
                  
                  
                  43.2
                  %Pro-Fund
      Administration, Ltd.  (3)
                  
                  
                  6,768,000
                  
                  
                  
                  45.5
                  %Robert
      Brooke (3)
                  
                  
                  2,538,000
                  
                  
                  
                  14.6
                  %Richard
      McKilligan (4)
                  
                  
                  846,000
                  
                  
                  
                  5.4
                  %All
      Directors and Executive Officers as a group (2 persons)
                  
                  
                  3,384,000
                  
                  
                  
                  18.5
                  %
 
 *
                Less
      than 1%
 (1)
                Paul
      Kessler exercises investment and voting control over the shares held by
      Bristol Investment Fund, Ltd.
 (2)
                Ivan
      Nygaard exercises investment and voting control over the shares held by
      Pro-Fund Administration, Ltd
 (3)
                Includes
      options to purchase 2,538,000 shares of common stock at an exercise price
      of $0.00067 per share.
  (4)
                Includes
      options to purchase 846,000 shares of common stock at an exercise price of
      $0.00067 per share.
  Change
of Control
  To the
knowledge of management, there are no present arrangements or pledges of
securities of our company that may result in a change in control of the
Company.
 
 Equity
Compensation Plan Information
 
 In
December 2008, we established the 2008 Equity Compensation Plan (the “Plan”).
The Plan was approved by our Board of Directors and security holders holding a
majority of the shares of our common stock outstanding. The purpose of the Plan
is to grant stock and stock options to purchase our common stock to our
employees and key consultants. The total amount of shares subject to the Plan is
6,000,000 shares. As of September 25, 2008, we had granted 3,384,000 options
under the Plan. The following table provides information as of August 31, 2008
with respect to the Plan, which is the only compensation plan under which our
equity securities are authorized for issuance.
 
 Plan category
                              
                              Number of securities to be
                                issued upon exercise of
                                outstanding options,
                                warrants and rights
                              
                              
                              Weighted-average
                                exercise price of
                                outstanding options,
                                warrants and rights
                              
                              
                              Number of securities
                                remaining available
                                for future issuance
                                under equity
                                compensation plans
                                (excluding securities
                                reflected in column (a))(a)
                              
                              
                              (b)
                              
                              
                              (c)Equity
      compensation plans approved by security holders
                              
                              
                              3,384,000
                              
                              
                              $
                              0.00067
                              
                              
                              
                              2,616,000Equity
      compensation plans not approved by security holders
                              
                              None
                              
                              
                              
                              
                              
                              
                              NoneTotal
                              
                              
                              3,384,000
                              
                              
                              
                              
                              
                              
                              
                              2,616,000
 
 Item
13.  Certain Relationships and Related Transactions, and Director
Independence.
  Described
below are certain transactions or series of transactions since September 1, 2007
between us and our subsidiaries and our executive officers, directors and the
beneficial owners of 5% or more of our common stock, on an as converted basis,
and certain persons affiliated with or related to these persons, including
family members, in which they had or will have a direct or indirect material
interest in an amount that exceeds the lesser of $120,000 or one percent of the
average of our total assets at year end for the last two completed fiscal years,
other than compensation arrangements that are otherwise required to be described
under “Executive Compensation.”
  15
 
 Richard
McKilligan, our Chief Financial Officer, is also a director of Bristol
Investment Fund, Ltd., which holds 6,429,600 shares, or 43.2%, of the Company’s
common stock.  Mr. McKilligan is also the Chief Financial Officer and
General Counsel of Derycz Scientific, Inc., of which Bristol Investment Fund,
Ltd. is a shareholder.
  On August
21, 2008, the Company entered
into a license agreement which gives the Company exclusive rights to protein
therapeutics being developed for the treatment of cancer and drug-resistant
bacterial infections (e.g. MRSA) with Hamilton Atlantic, which is owned by
Bristol Investment Fund, ltd and Pro-Fund Administration, Ltd., which are both
shareholders of the Company.
 
 Director
Independence
  None of
the members of the Company’s Board of Directors are independent directors as
that term is defined by NASDAQ Rule 4200(a)(15). The Company’s currently does
not have an Audit Committee. None of the members of the Company’s Board of
Directors meet the Audit Committee independence requirements of NASDAQ Rule
4350(d)(2).
 
 Item
14.  Principal Accounting Fees and Services.
 
 Summary
of Principal Accounting Fees for Professional Services Rendered
 
 The
following table presents the aggregate fees for professional audit services and
other services rendered by Larry O’Donnell, CPA, P.C., our former independent
registered public accountants in the fiscal years ended August 31, 2007and
2008.  No fees were been paid to Weinberg & Company, P.A., our
current independent registered public accountants in the fiscal years ended
August 31, 2007 or 2008.
 
 Year Ended August 31, 2008
                          
                          
                          Year Ended August 31, 2007Audit
      Fees
                          
                          $
                          7,511
                          
                          
                          $
                          1,775Audit-Related
      Fees
                          
                          
                          0Tax
      Fees
                          
                          
                          0All
      Other Fees
                          
                          
                          -$
                          7,511
                          
                          
                          $
                          1,775
 
 Audit Fees consist of fees
billed for the annual audit of our financial statements and other audit services
including the provision of consents and the review of documents filed with the
SEC.
  We do not
have an independent audit committee and the full Board of Directors, therefore,
serves as the audit committee for all purposes relating to communication with
our auditors and responsibility for our audit. All engagements for audit
services, audit- related services and tax services are approved in advance by
our full Board of Directors. Our Board of Directors has considered whether the
provision of the services described above for the fiscal years ended August 31,
2007 and 2008, is compatible with maintaining the auditor’s
independence.
  All audit
and non-audit services that may be provided by our principal accountant to us
shall require pre-approval by the Board of Directors. Further, our auditor shall
not provide those services to us specifically prohibited by the SEC, including
bookkeeping or other services related to the accounting records or financial
statements of the audit client; financial information systems design and
implementation; appraisal or valuation services, fairness opinion, or
contribution-in-kind reports; actuarial services; internal audit outsourcing
services; management functions; human resources; broker-dealer, investment
adviser, or investment banking services; legal services and expert services
unrelated to the audit; and any other service that the Public Company Accounting
Oversight Board determines, by regulation, is impermissible.
  16
  PART
IV
 
 Item
15.  Exhibits, Financial Statements Schedules.
 
 (a)
Documents filed as a part of this report
 
 (1) Financial
Statements
 
 The financial statements of
Percipio Biotherapeutics, Inc. andWeinberg & Company, P.A.’s report dated January 16,
2009, are incorporated by reference to Item 8 of this
report.
 
 (2) Financial Statement
Schedules
 
 Not
required.
 
 (b)
Exhibits
 
 Exhibit
                      Number
                    
                    Description3.1
                    
                    Articles
      of Incorporation (1)3.2
                    
                    Bylaws
      (1)3.3
                    
                    Articles
      of Merger (2)3.4
                    
                    Certificate
      of Amendment to the Certificate of Incorporation (2)3.5
                    
                    Articles
      of Amendment of Sunburst Acquisitions III, Inc (3)4.1
                    
                    Form
      of Convertible Promissory Notes issued August 2008 (4)10.1
                    
                    2008
      Equity Compensation Plan (5)10.2
                    
                    Robert
      Brooke employment agreement (4)10.3
                    
                    Richard
      McKilligan employment agreement (4))10.4
                    
                    License
      Agreement entered by and between Sunburst Acquisitions III, Inc. and
      Hamilton Atlantic, a Cayman Islands company - Cancer Therapeutic License
      (6)10.5
                    
                    License
      Agreement entered by and between Sunburst Acquisitions III, Inc. and
      Hamilton Atlantic, a Cayman Islands company - MRSA Therapeutic License
      (6)10.6
                    
                    License
      Agreement with Cancer Research Technology Limited (7)_31.1
                    
                    Rule
      13a-14(a)/15d-14(a) Certification of Chief Executive Officer
    *31.2
                    
                    Rule
      13a-14(a)/15d-14(a) Certification of Chief Financial Officer
    *32.1
                    
                    Section
      1350 Certification of Chief Executive
  Officer  *32.2
                    
                    Section
      1350 Certification of Chief Financial Officer
*
 
 * Filed
herewith.
 
 (1)
Incorporated by reference to the Registration Statement on Form 10-SB filed with
the Securities and Exchange Commission on December 29, 1997.
 
 (2)  Incorporated
by reference to the Current Report on the Form 8-K filed with the Securities and
Exchange Commission on October 31, 2008.
 
 (3)  Incorporated
by reference to the Current Report on the Form 8-K filed with the Securities and
Exchange Commission on January 24, 2007.
 
 (4)  Incorporated
by reference to the Current Report on the Form 8-K filed with the Securities and
Exchange Commission on August 11, 2008.
  17
  (5)  Incorporated
by reference to the Information Statement on the Schedule 14C filed with the
Securities and Exchange Commission on November 21, 2008.
 
 (6)  Incorporated
by reference to the Current Report on the Form 8-K filed with the Securities and
Exchange Commission on August 27, 2008.
 
 (7)  Incorporated
by reference to the Current Report on the Form 8-K filed with the Securities and
Exchange Commission on November 26, 2008.
 
 18
  SIGNATURES
 
 Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
 
 PERCIPIO BIOTHERAPEUTICS,
      INC.By:
              /s/
      Robert BrookeRobert
      BrookeDate: February 13,
      2009
              
              Chief
      Executive Officer
  Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the
capacities and on the dates indicated.
 
 Signature
                        
                        Title
                        Date/s/Robert
      BrookeRobert
      Brooke
                        
                        Chief
      Executive Officer (Principal Executive
                        February
      13, 2009Officer)
      and Chairman of the Board/s/
      Richard McKilligan
                        
                        Chief
      Financial Officer (Principal FinancialRichard
      McKilligan
                        
                        and
      Accounting Officer), Secretary and
                        February
      13, 2009Director
 
 19
  EXHIBIT
INDEX
  Exhibit
                Number
              
              Description3.1
              
              Articles
      of Incorporation (1)3.2
              
              Bylaws
      (1)3.3
              
              Articles
      of Merger (2)3.4
              
              Certificate
      of Amendment to the Certificate of Incorporation (2)3.5
              
              Articles
      of Amendment of Sunburst Acquisitions III, Inc (3)4.1
              
              Form
      of Convertible Promissory Notes issued August 2008 (4)10.1
              
              2008
      Equity Compensation Plan (5)10.2
              
              Robert
      Brooke employment agreement (4)10.3
              
              Richard
      McKilligan employment agreement (4))10.4
              
              License
      Agreement entered by and between Sunburst Acquisitions III, Inc. and
      Hamilton Atlantic, a Cayman Islands company - Cancer Therapeutic License
      (6)10.5
              
              License
      Agreement entered by and between Sunburst Acquisitions III, Inc. and
      Hamilton Atlantic, a Cayman Islands company - MRSA Therapeutic License
      (6)10.6
              
              License
      Agreement with Cancer Research Technology Limited (7)_31.1
              
              Rule
      13a-14(a)/15d-14(a) Certification of Chief Executive Officer
    *31.2
              
              Rule
      13a-14(a)/15d-14(a) Certification of Chief Financial Officer
    *32.1
              
              Section
      1350 Certification of Chief Executive
  Officer  *32.2
              
              Section
      1350 Certification of Chief Financial Officer
*
  (1)
                Incorporated
      by reference to the exhibit of the same number to the
      registrant’s
 (2)
                Incorporated
      by reference to the exhibit of the same number to the
      registrant’s
 (3)
                  Filed
      herewith.(4)
                  Incorporated
      by reference to the Current Report on the Form 8-K filed with the
      Securities and Exchange Commission on August 11,
    2008.
 (5)
                Incorporated
      by reference to the Information Statement on the Schedule 14C filed with
      the Securities and Exchange Commission on November 21,
    2008.
 (6)
                Incorporated
      by reference to the Current Report on the Form 8-K filed with the
      Securities and Exchange Commission on August 27,
  2008.
 (7)
                Incorporated
      by reference to the Current Report on the Form 8-K filed with the
      Securities and Exchange Commission on November 26,
  2008.
  20